Uterine Cancer Awareness Month | |
|
NRG Oncology Publication Demonstrates Radiotherapy Should Remain Standard of Care, Future Research Should Consider Tumor Subsets
| |
Recently reported results from the NRG-GOG 0238 clinical trial that tested radiotherapy with or without cisplatin-based chemotherapy for recurrences in endometrial cancer indicated that radiotherapy should remain the standard of care for this population. Patients treated with chemotherapy and radiotherapy experience higher acute toxicities without improvement in progression-free survival as compared to patients treated with radiotherapy alone. These results were published in Journal of Clinical Oncology. | |
|
NRG-GY018 Demonstrates Improved PFS Outcomes with the Addition of Pembrolizumab to Chemotherapy for Women with Advanced or Recurrent Endometrial Cancer
| |
Protocol-specified first interim analysis results from the Phase III NRG-GY018 clinical trial comparing pembrolizumab combined with standard of care chemotherapy followed by maintenance pembrolizumab to placebo combined with chemotherapy followed by placebo indicated that patients with stage III-IV or recurrent endometrial cancer who received pembrolizumab exhibited improved progression-free survival outcomes. These findings were presented as a late-breaking abstract at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer and are also simultaneously being published in the New England Journal of Medicine. Read the press release here. | |
National Cancer Survivors Month | |
|
The Advocate Angle
*A new segment in NRG Currents created by our Patient Advocate Committee*
| |
|
Advancing Research: NRG Advocates Call to Action for Uterine Cancer Awareness Month and National Cancer Survivors Month
| |
Article by Marlyn Molero & Tambre Leighn, Co-Vice Chairs of NRG Oncology’s Patient Advocate Committee | |
June is a time of dual significance in the cancer community as we celebrate National Cancer Survivors Month and Uterine Cancer Awareness Month. For those of us on the Patient Advocate Committee, this is a moment to reflect on the unique challenges faced by uterine cancer survivors particularly within the context of clinical trials. While significant strides have been made in the treatment of uterine cancer, survivors continue to navigate a complex landscape of physical, emotional, and social challenges that deserve attention from the research community. | |
NRG New Protocols Under Development & Study News | |
|
NRG-CC012CD Opens to Accrual: Addressing Patient Symptom Monitoring and Management
| |
|
NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON)
NRG Oncology recently activated the NRG-CC012CD clinical study out of the group’s National Cancer Institute (NCI) Community Oncology Research Program (NCORP) research base. There are a vast number of patients who are currently treated with oral anti-cancer agents, and the average cost of receiving or administering these agents is high. The burden of multiple symptoms experienced while taking anti-cancer oral agents has historically been the main driver of treatment interruptions and unscheduled health services use. The way to effectively reduce these risks is through telephone symptom management and monitoring, however, implementation of regular symptom monitoring can be challenging to practices, and patients need support for symptom self-management, especially those who experience depressive and anxiety symptoms.
| |
|
New Protocols Under Development
| |
|
NRG Oncology has issued a chart of new protocols under development. These protocols will include the study’s disease site, title, Principal Investigator, and any comments pertaining to the study’s anticipated activation.
The updated listing as of May 31st can be found here.
| |
|
|
FORTE enrolled its 1600th participant on June 6, 2024!
| |
|
Register for the July 26th FORTE Workshop
| |
|
The NRG Summer 2024 Meeting will be held in Denver, CO at the Sheraton Denver Downtown Hotel. This will be an in-person meeting, with select sessions available via Zoom. Please visit our registration portal to view specific session formats.
The FORTE Workshop will be in-person only on July 26 at 1:15 local time. Register today to hear updates on NRG-CC005 at the Summer Meeting!
Registration Deadline: July 2nd, 2024
Late Registration: After July 2nd, 2024 (includes same-day registration information – Attendees will be charged a $50 fee for late registration)
* Rates will change on the cutoff date at 11:59 p.m. MDT.
| |
Protocol Support Committee (PSC) Column | |
|
PSC at the NRG 2024 Summer Meeting
| |
|
Article submission from the NRG Oncology PSC Education & Training Committee
The NRG Oncology Summer meeting is fast approaching! The Protocol Support Committee (PSC) has been working hard to put together a variety of programing specifically for our clinical research professional (CRP) members. We are excited to share a sneak peek of what to expect at the 2024 NRG Oncology July Meeting in Denver:
| |
|
HDC Annual Symposium Recording Now Available
| |
The recording of the NRG Health Disparities Committee Annual Symposium Aligning Clinical Trial Development with an Aging Population – Challenges and Opportunities for Older Adults with Cancer (April 16, 2024) is now posted under the Health Disparities Meetings, Workshops & Symposia on the HDC page on the NRG Oncology website (login required). | |
|
HDC Special Meeting Recording Now Available
| |
The NRG Health Disparities Committee (HDC) Special Program-Engagement Opportunities and Supportive Resources within the NRG Health Disparities Committee (May 10, 2024) is now posted under the Health Disparities Meetings, Workshops & Symposia on the HDC page on the NRG Oncology website (login required). | |
NRG Oncology Announces New Leadership of Three Committees | |
NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced a new Chair to the NRG Genitourinary (GU) Cancer Committee, a new Vice-Chair of the NRG Radiation Oncology Committee, and a new Chair and Vice-Chair of the NRG Developmental Therapeutics Gynecologic Cancer Phase I Subcommittee. Read the Press Release | |
|
NRG Oncology Appoints New Vice-Chairs for their Patient Advocate Committee | |
NRG Oncology recently announced two new Vice-Chairs to co-lead the NRG Patient Advocate Committee (PAC) alongside the current PAC Committee Chair, Dorothy Erlanger. Marlyn Molero, was appointed as Vice-Chair of the NRG PAC. Marlyn is a clinical researcher in the oncology area with Commonspirit Research Institute as well as a Spanish interpreter at Vituity. Tambre Leighn, was also appointed as Vice-Chair of the NRG PAC. Tambre is a highly regarded consultant, trainer, and speaker in the healthcare industry. Read the Press Release | |
NRG Oncology Abstract Considered “Best of ASCO” for 2024 Shows Difference in Outcomes for Node-Negative Versus Node-Positive Pancreatic Cancer Patients when Adding Chemoradiation to Systemic Therapy | |
NRG Oncology recently reported the results from the radiotherapy randomization, which was the second step of their NRG-RTOG 0848 clinical study comparing adjuvant chemotherapy with or without chemoradiation for patients with resected periampullary pancreatic adenocarcinoma. The trial data did not show that the addition of radiation and chemotherapy to adjuvant systemic therapy improved overall survival (OS) for all patients on the study, however, OS was improved among node-negative patients. OS was essentially the same between treatment arms for node positive patients. The trial data also showed that disease-free survival (DFS) was improved with the addition of radiation and chemotherapy to adjuvant systemic therapy, driven by the DFS improvement in node negative patients. The addition of chemoradiation did not increase grade 4 or 5 adverse events. These results were presented as at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and was distinguished as a “Best of ASCO” abstract. Read the Press Release | |
NRG Oncology Biospecimen Bank (PGH) relocates to Nova Place Campus | |
The grand opening of the Pittsburgh location of the NRG Oncology Biospecimen Bank/NSABP Foundation Division of Pathology was recently celebrated with a ribbon cutting event on May 23, 2024. Norman Wolmark, MD (NRG Group Chair/Contact Principal Investigator and NSABP Foundation Chair) was joined by NSABP Foundation leaders, Pennsylvania State Senators Jay Costa, Devlin Robinson, and Wayne Fontana; and Pat Halpin-Murphy, President/Founder of the Pennsylvania Breast Cancer Coalition to commemorate the event. Read the Press Release. | |
Dr. Wolmark presents Keynote Lecture at COSM24 | |
Congratulations to Dr. Norman Wolmark on a memorable Keynote Lecture, "Clinical Trials and the Retreat from Radical Operations," presented at the Combined Otolaryngology Spring Meeting (COSM) held in Chicago in May. | |
| |
|
Registration is open for the NRG Summer 2024 Meeting. Keep checking the NRG website, newsletters, email broadcasts, and social media for updates as they become available.
| | | | |
